Slides
Page 1
9M and Q3 2026 Results Conference call and webcast for investors and analysts 30 October 2026
Page 2
2 Cautionary statements regarding forward-looking statements In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter 'the Group') provides the following cautionary statement: This document contains certain forward -looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, statements about expected revenues, margins, earnings per share or other financial or other me asures. Although the Group believes its expectations are based on reasonable assumptions, any forward -looking statements, by their very nature, invol ve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from t hose predicted. The forward-looking statements reflect knowledge and information available at the date of preparation of this document and the Group undertakes no obligation to update these forward -looking statements. The Group identifies the forward -looking statements by using the words 'anticipates', 'believes', 'expects', 'intends' and similar expressions in such statements. Important factors that could cause actual result s to differ materially from those contained in forward -looking statements, certain of which are beyond the Group's control, include, among other things: the risk of failure or delay in delivery of the pipeline or launch of new medicines; the risk of failure to meet regulatory or ethical requirements for medicine development or approval; the risk of failures or delays in the quality or execution of the Group's commercial strategies; the risk of pricin g, affordability, access and competitive pressures; the risk of failure to maintain supply of compliant, quality medicines; the risk of illegal trade in t he Group's medicines; the risk of reliance on third-party goods and services; the risk of failure in information technology or cybersecurity; the risk of failu re of critical processes; the risk of failure to collect and manage data and artificial intelligence in line with legal and regulatory requirements and str ategic objectives; the risk of failure to attract, develop, engage and retain a diverse, talented and capable workforce; the risk of failure to meet sustain ability targets, regulatory requirements or stakeholder expectations with respect to the environment; the risk of failure to meet regulatory and ethical expectations on commercial practices, including anti -bribery anti-corruption, anti-fraud and scientific exchanges; the risk of the safety and ef ficacy of marketed medicines being questioned; the risk of adverse outcome of litigation and/or governmental investigations; intellectual proper ty risks related to the Group's products; the risk of failure to achieve strategic plans or meet targets or expectations; the risk of geopolitical an d/or macroeconomic volatility disrupting the operation of the Group ’s global business; the risk of failure in internal control, financial reporting or the occurrence of fraud; and the risk of unexpected deterioration in the Group's financial position.
Page 3
3 9M and Q3 2026 Results Conference call agenda CEO Opening Remarks Pascal Soriot Chief Executive Officer Financial Results Aradhana Sarin Chief Financial Officer Oncology Haematology Dave Fredrickson EVP , Oncology Haematology Business Susan Galbraith EVP , Oncology Haematology R&D BioPharmaceuticals Ruud Dobber EVP , BioPharmaceuticals Business Sharon Barr EVP , BioPharmaceuticals R&D Rare Disease Marc Dunoyer Chief Executive Officer , Alexion CEO Closing Remarks, Q&A Pascal Soriot Chief Executive Officer
Page 4
Please ensure you have added the correct confidentiality statement. Type the correct statement: ‘Company Restricted’ or ‘Strictly Confidential’ . No statement is needed for public information. ! CEO Opening Remarks Pascal Soriot CHIEF EXECUTIVE OFFICER 44
Page 5
All growth rates at CER compared to 9M 2025. 1. Revenue growth calculated excluding Farxiga and Brilinta following LOEs in certain major markets. 2. Since FY 2025 results. Appendix: Glossary. 5 Strong 9M 2026 execution builds confidence in sustainable growth through the next decade MEANINGFUL PROGRESS FOR OUR PIPELINE2 SUSTAINED COMMERCIAL MOMENTUM +7% Total Revenue +14% Core EPS positive Phase III programme readouts12 1st approval for 4 new medicines +12% Total Revenue, ex. Farxiga and Brilinta1 1st Phase III data for 3 NMEs tozorakimab efzimfotase alfa sonesitatug vedotin
Page 6
ID = Infectious Disease (previously Vaccines & Immune Therapies). Due to rounding, the sum of the percentages may not agree t o totals. 1. All growth rates at CER compared to 9M 2025. Appendix: Glossary. 6 Growth driven by diverse therapy areas and global presence 9M 2026 | % Product Revenue by geography 9M 2026 | % Product Revenue by therapy area Strength across therapy areas 9M 2026 | +6% Product Revenue ($m)1 Growth across geographies 9M 2026 | + 6% Product Revenue ($m)1 Oncology 47% CVRM 18% R&I 16% ID 2% Other 1% Rare Disease 16% US 42% Europe 23% Ex-China 15% China 12% ERoW 8% Oncology Rare DiseaseBioPharmaceuticals 19,788 5,430 10,528 3,937 7,085 US Emerging Markets Europe ERoW +7% +7% +10% +3% +8% -3% Ex-China: China: 7,54421,888 8,616 7,268 ID: 735 +16% +10% -15% -5% +11% R&I: CVRM:
Page 7
Twelve positive Phase III programme readouts YTD 7 2026 positive Phase III readouts represent >$10bn in non-risk-adjusted peak year revenue3 OBERON TITANIA MIRANDA tozorakimab COPD I CANUltomiris IgAN NILEImfinzi 1L urothelial cancer CHESTNUT MULBERRY HICKORY efzimfotase alfa HPP VOLGAImfinzi MIBC SAFFRON Tagrisso + Orpathys 2-3L EGFRm NSCLC EMERALD-3Imfinzi locoregional HCC CLARITY-Gastric01 sone-ve CLDN18.2+ 2L+ gastric cancer DESTINY-Lung04Enhertu HER2m NSCLC CROSSINGTezspire EoE SANOVO1 Tagrisso + Orpathys 1L EGFRm NSCLC DeLLphi-3052Imfinzi ES-SCLC 1. SANOVO trial conducted in China. 2. DeLLphi -305 trial is sponsored by Amgen, with partial funding and Imfinzi provided by AstraZeneca. 3. Combined non -risk-adjusted Peak-Year Revenue of all positive Phase III programmes in 2026, includin g those depicted on the slide. Individual PYR may occur at different time points for different trials. Collaboration partners: Daiichi Sankyo (Enhertu), Amgen (Tezspire), Hutchmed (Orpathys). Appendix: Glossary.
Page 8
Enhancing the value of AstraZeneca’s ADC portfolio through strategic collaboration with Summit 8 Positions AstraZeneca as a leader in the ADC + next-generation IO bispecific space – Broadens and maximises AZ assets across key tumour types by addressing segmented treatment approaches – Strategic investment in Summit accelerates development of ivonescimab + ADCs across tumour types sone-ve + ivonescimab Datroway + ivonescimab Other AZ assets + ivonescimab Gastrointestinal cancers Breast and lung cancers Planned collaboration Collaboration partner: Daiichi Sankyo (Datroway). Appendix: Glossary.
Page 9
9 Strategically investing to deliver growth beyond 2030 Significant progress across our transformative technologies in 9M 2026 Unprecedented OS benefit with sone-ve for 2L+ gastric cancer in CLARITY-Gastric01 1st puxi-sam Phase III H2 2027 and 3 Phase IIIs for torvu-sam initiated in 2026 15 Phase III trials across 9 tumour types Maximising ADC opportunity with Summit collaboration of ivonescimab + AZ ADCs 1st Phase III readouts for rilvegostomig and volrustomig in H2 2027 6 ongoing Phase III trials for AZ IO bispecifics + ADCs 3 ongoing Phase IIIs of AZD0120 in multiple myeloma 4 further clinical-stage cell therapies Early trials for AZD0120 ongoing across range of autoimmune diseases Ongoing surovatamig Phase IIIs in follicular lymphoma and DLBCL 4 additional TCEs in early-stage development Extending surovatamig into autoimmune diseases with early trials underway 1st Phase III data for laroprovstat and laroprovstat + rosuvastatin H1 2027 3 Phase III trials initiated for lenbelintide (AZD6234) 10 Phase III trials ongoing for elecoglipron T-cell engagers ADCs and radio- conjugates Next-gen IO bispecifics Cell therapy Weight management and CV risk factors Appendix: Glossary.
Page 10
Please ensure you have added the correct confidentiality statement. Type the correct statement: ‘Company Restricted’ or ‘Strictly Confidential’ . No statement is needed for public information. ! Financial Results Aradhana Sarin CHIEF FINANCIAL OFFICER 10
Page 11
11 9M and Q3 2026 – Reported profit and loss 9M 2026 $m CER change % % Total Revenue Q3 2026 $m CER change % % Total Revenue - Product Sales 43,962 5 94 15,066 5 93 - Alliance Revenue 2,806 32 6 1,107 36 7 Product Revenue 46,768 6 100 16,173 7 100 - Collaboration Revenue 113 23 - 36 >3x - Total Revenue 46,881 7 100 16,209 7 100 Gross Margin 83% +1pp 82% +1pp - R&D expense (11,439) 9 24 (3,894) 7 24 - SG&A expense (15,679) 7 33 (5,108) - 32 Total operating expense1 (27,555) 7 59 (9,153) 3 56 Other operating income and expense 618 >2x 1 277 >3x 2 Operating profit 11,797 10 25 4,387 26 27 Tax rate 18% 21% Reported EPS $5.62 11 $2.02 26 Due to rounding, the sum of the dollar values and percentages may not agree to totals. Absolute values at actual exchange rat es; changes at CER. 1. Total operating expense includes distribution, R&D and SG&A expenses. Appendix: Glossary.
Page 12
12 Due to rounding, the sum of the dollar values and percentages may not agree to totals. Absolute values at actual exchange rat es; changes at CER. 1. Total operating expense includes distribution, R&D and SG&A expenses. Appendix: Glossary. 9M and Q3 2026 – Core profit and loss 9M 2026 $m CER change % % Total Revenue Q3 2026 $m CER change % % Total Revenue - Product Sales 43,962 5 94 15,066 5 93 - Alliance Revenue 2,806 32 6 1,107 36 7 Product Revenue 46,768 6 100 16,173 7 100 - Collaboration Revenue 113 23 - 36 >3x - Total Revenue 46,881 7 100 16,209 7 100 Gross Margin 83% +1pp 82% +1pp - R&D expense (10,768) 5 23 (3,645) 3 22 - SG&A expense (11,818) 4 25 (3,909) 2 24 Total operating expense1 (23,022) 5 49 (7,704) 2 48 Other operating income and expense 618 >2x 1 277 >2x 2 Operating profit 16,365 14 35 5,855 20 36 Tax rate 19% 21% Core EPS $8.00 14 $2.79 19
Page 13
13 Net debt/EBITDA 1.2x $bn $19.5bn $21.2bnEBITDA4 Due to rounding, the sum of the dollar values and percentages may not agree to totals. 1. Capital expenditure on tangible ass ets and software-related intangible assets. 2. Comprises purchase and disposal of intangible assets (excluding software-related assets, including AZ Forest), purchase and disposal of non -current asset investments, payments to associates an d joint ventures, payments to acquire non -controlling interests, disposal of investments in associates and joint ventures, acquisitions of subsidiaries, net of acquired net debt and payment of contingent consideration on business co mbinations. The Company mainly uses debt issuance or available cash to finance new Business Development opportunities. 3. Comprises mainly shares purchased by Employee Benefit Trust and recognition of Kendall Square lease liabili ty. 4. Rolling 12-month EBITDA. AstraZeneca credit ratings: Moody’s: short -term rating P-1, long-term rating A1, outlook positive. S&P Global Ratings: short -term rating A-1, long-term rating A+, outlook stable. 5. If foreign exchange rat es for October 2026 to December 2026 were to remain at the average rates seen in September 2026. Appendix: Glossary. Total Revenue Core EPS Anticipated to increase by a mid-to-high single-digit percentage Anticipated to increase by a low double-digit percentage FY 2026 Guidance (CER) • Core tax rate expected to be between 18-22% • Anticipated FX impact5: low single-digit positive impact on Total Revenue and neutral on Core EPS FY 2026 guidance reiterated Capital allocation priorities remain unchanged Net debt end 2025 CFO CapEx1 Deal payments and receipts2 Dividend Net debt end 9M 2026 Other3 23.4 10.9 2.3 4.3 5.0 25.8 1.8
Page 14
Please ensure you have added the correct confidentiality statement. Type the correct statement: ‘Company Restricted’ or ‘Strictly Confidential’ . No statement is needed for public information. ! Oncology Dave Fredrickson ONCOLOGY HAEMATOLOGY BUSINESS Susan Galbraith ONCOLOGY HAEMATOLOGY R&D 14
Page 15
All growth rates at CER compared to same financial period in 2025. 1. Others is inclusive of Datroway, Etcamah and Zegfrovy. 2. Approval based on results from DESTINY -PanTumor02, DESTINY-PanTumor03, DESTINY-Lung01 and DESTINY-CRC02. Collaboration partners: Daiichi Sankyo ( Enhertu, Datroway), Merck & Co., Inc. (Lynparza), Hutchmed (Orpathys). Appendix: Glossary. 15 Oncology – 9M and Q3 2026 Total Revenue +16% in 9M 2026 and +17% in Q3, driven by continued global demand across key medicines Q3 2026: key dynamics Tagrisso Imfinzi + Imjudo Calquence Enhertu Truqap Lynparza (PR) Others1 Lynparza (CR) Oncology 9M 2026 $21.9bn, +16% • Tagrisso +12%, sustained 1L leadership with continued FLAURA2 uptake in growing combo market • Imfinzi +26%, Imjudo +25%, robust global demand growth across tumours • Calquence +16%, BTKi leadership in 1L CLL across top 8 markets • Enhertu +35%, strong global demand growth, US launch momentum • Truqap +9%, continued ex-US growth, 2L US share at peak • Datroway $78m, increasing share in 2L+ EGFRm lung, early uptake in TNBC Key regulatory approvals: • US: Etcamah SERENA-6 • EU, JP , CN: Datroway TROPION-Breast02, Enhertu DESTINY-Breast09 & 05 • JP: Imfinzi POTOMAC • CN: Enhertu DESTINY-PanTumor022 0 500 1,000 1,500 2,000 2,500 3,000 3,500 4,000 4,500 5,000 5,500 6,000 6,500 7,000 7,500 8,000 8,500 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2024 2025 2026 Total Revenue ($m)
Page 16
1. DeLLphi-305 trial is sponsored by Amgen, with partial funding and Imfinzi provided by AstraZeneca. Collaboration partners: Daiichi Sankyo ( Enhertu), Hutchmed (Orpathys). Appendix: Glossary. 16 Oncology – reshaping practice across tumour types Five presidential plenary sessions of AstraZeneca oncology data across WCLC and ESMO Enhertu Expanding in HER2m NSCLC DESTINY-Lung04 Imfinzi DeLLphi-3051 Consolidating leadership in SCLC sone-ve CLARITY-Gastric01 New potential SoC in CLDN18.2+ gastric cancer VOLGA Extending Imfinzi across spectrum of MIBC Underpins AstraZeneca Oncology strategy – moving treatments earlier in disease and improving outcomes through novel combinations SANOVOSAFFRON Tagrisso + Orpathys Reinforcing Tagrisso SoC backbone in EGFRm NSCLC Featured in a presidential session at the congress
Page 17
Please ensure you have added the correct confidentiality statement. Type the correct statement: ‘Company Restricted’ or ‘Strictly Confidential’ . No statement is needed for public information. ! BioPharmaceuticals 17 Ruud Dobber BIOPHARMACEUTICALS BUSINESS Sharon Barr BIOPHARMACEUTICALS R&D 17
Page 18
All growth rates at CER compared to same financial period in 2025. 1. Others includes Baxfendy. Collaboration partners: Amgen (Tezspire), Ionis (Wainua). Appendix: Glossary. BioPharmaceuticals – 9M and Q3 2026 Total Revenue -5% to $16.7bn; CVRM LoE impact partially offset by growth in R&I Q3 2026: key dynamics • Fasenra +14%, sustained IL -5 leadership in asthma, EGPA growth, ongoing China launch • Breztri +14%, fastest growing medicine in expanding FDC triple class; asthma launch • Tezspire +51%, sustained demand growth in severe asthma supported by nasal polyps launch • Saphnelo +32%, increasing penetration of i.v. formulation; s.c. launch in US, EU, Japan • Farxiga (23%), generic competition in US and Japan; VBP in China; growth in other regions • Wainua +17%, demand growth in ATTR -PN • Baxfendy $9m, launch progressing well R&I 9M 2026 $7.3bn, +10% Fasenra Breztri Tezspire Saphnelo Symbicort Others CVRM 9M 2026 $8.7bn, -14% Farxiga Brilinta Lokelma Wainua Others1 Key regulatory approvals : • EU, JP (Breztri KALOS / LOGOS) 0 500 1,000 1,500 2,000 2,500 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2024 2025 2026 Total Revenue ($m) 0 500 1,000 1,500 2,000 2,500 3,000 3,500 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2024 2025 2026 Total Revenue ($m) 18
Page 19
Represents non-risk adjusted peak year revenue. 1. Based on OBERON and TITANIA Phase III studies. N Engl J Med. 2026 DOI: 10.1056/NEJMoa2606998. 2. Based on US Prescribing Information for mepolizumab. 3. Based on US Prescribing Information for dupilumab. 4. Annualised rate of moderate to severe exacerbations based on a key secondary endpoint. 5. Annualised reduction in moderate to severe exacerbations based on pooled data for tozorakimab from OBERON and TITANIA trials. 6. UEGW 2026, Bredenoord, A. J. Long-term efficacy and safety of tezepelumab over 52 weeks in adults and adolescents with eosinophilic esophagitis: Results from the Phase 3 CROSSING study. 7. Data at week 24 based on results of 210mg and 420 mg Tezspire Q4W dose. 3.5% of patients on placebo achieved histologic remission at week 24. Collaboration partners: Amgen ( Tezspire). Appendix: Glossary. 19 BioPharmaceuticals – Key Phase III data support our growth ambitions tozorakimab | Broad COPD efficacy reinforces $5bn+ PYR potential Tezspire | Positive Phase III EoE data adds to multi-blockbuster potential Up to 69% of patients achieved histologic remission 6,7 Up to 7.3 point DSQ score improvement vs placebo 6,7 1st biologic to sustain benefits through week 52 vs placebo Compelling Phase III data across two key assets strengthens long-term growth outlook CROSSING PHASE III 6OBERON AND TITANIA PHASE III 1 GOLD stage GOLD 4 GOLD 3 GOLD 2 GOLD 1 mepolizumab2 dupilumab3 tozorakimab BEC <150 150–300 ≥300 Exacerbation reduction4 All comers: 30% reduction in exacerbations 5 BEC <150 23% BEC ≥150 34% BEC ≥300 43%
Page 20
Please ensure you have added the correct confidentiality statement. Type the correct statement: ‘Company Restricted’ or ‘Strictly Confidential’ . No statement is needed for public information. ! Rare Disease Marc Dunoyer CHIEF EXECUTIVE OFFICER, ALEXION 20 20
Page 21
Rare Disease – 9M and Q3 2026 Total Revenue $7.5bn driven by key brands, advancing multiple launches across the portfolio C5 Franchise • Ultomiris +19%, growth across indications, led by neurology • Soliris (35%), successful conversion to Ultomiris and additional impact from biosimilars in US and EU Beyond Complement • Strensiq +34%, continued strong global demand from patients with HPP • Koselugo +9%, continued growth, including adult indication, benefitted from tender order timing in EM Ultomiris1 Soliris Strensiq Koselugo (PS) Koselugo (CR) Others2 0 500 1,000 1,500 2,000 2,500 3,000 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2024 2025 2026 Total Revenue ($m) All growth rates at CER compared to same financial period in 2025. 1. Ultomiris Total Revenue includes sales of Voydeya. 2. Others includes Kanuma and Beyonttra (JP only). Collaboration partners: Merck & Co., Inc. ( Koselugo) concluded in August 2025, BridgeBio (Beyonttra). Appendix: Glossary. Rare Disease 9M 2026 $7.5bn, +11% Q3 2026: key dynamics Multiple launch opportunities I CAN IgAN Approved in US, filed in JP PREVAIL gMG efzimfotase alfa HICKORY/ MULBERRY / CHESTNUT HPP Approved in JP , positive CHMP in EU, filed in major markets Filed in major markets CAEL-301/2 AL-A Approved in JP US Priority Review 21
Page 22
1. G. Sinigiani et al August 2025, Journal of the American College of Cardiology: Heart Failure DOI 10.1016/j.jchf.2025.102549. 2. Available therapies include both silencers and stabilisers. Appendix: Glossary. 22 efzimfotase alfa | Expansion beyond Strensiq Ultomiris | Expanding into IgAN cliramitug | Differentiated TTR depleter MoA in ATTR-CM Rare Disease – expanding our leadership with multiple blockbuster opportunities Ultomiris demonstrated consistent efficacy across IgAN patients Focused on patients with higher risk of progression and inflammatory disease Leveraging established nephrology presence in rare diseases Phase III with hard composite endpoints across ACM and CV events on top of standard of care patients progress despite available therapies2 Blockbuster opportunity $3-5bn NRA PYR potential $3-5bn NRA PYR potential 1/31 cliramitug has potential to improve cardiac structure, and alter course of disease + Lower treatment burden + Better tolerability + Broader clinical data + Global expansion Better treatment continuity and broader patient reach
Page 23
Please ensure you have added the correct confidentiality statement. Type the correct statement: ‘Company Restricted’ or ‘Strictly Confidential’ . No statement is needed for public information. ! CEO Closing Remarks Pascal Soriot CHIEF EXECUTIVE OFFICER 2323
Page 24
Pipeline momentum continues through 2027 24 Key readouts support NME growth outlook >15 other high-value readouts TROPION-Lung07 | Datroway TROPION-Lung15 | Datroway ± Tagrisso PACIFIC-9 | Imfinzi + oleclumab/monalizumab reAZURE-PLUS | laroprovstat + rosuvastatin DAISY | Saphnelo IRIS | Saphnelo LAVENDER | Saphnelo TROPION-Breast03 | Datroway + Imfinzi TROPION-Breast05 | Datroway + Imfinzi PACIFIC-4 | Imfinzi CAPItello-292 | Truqap Bluestar-Endometrial01 | puxi-sam ARTEMIDE-Biliary01 | rilvegostomig eVOLVE-Cervical | volrustomig BaxPA | Baxfendy reAZURE-NAIVE | laroprovstat + rosuvastatin TILIA | tozorakimab H1 H2 Datroway laroprovstat balcinrenone/ dapagliflozin zibotentan/ dapagliflozin Etcamah saruparib AVANZAR 1L NSQ/NSQ TROP2+ NSCLC AZURE-LDL/AZURE-HeFH Dyslipidaemia BalanceD-HF HF + renal impairment ZENITH High Proteinuria CKD + high proteinuria CAMBRIA-1 HR+ eBC (adjuvant switch) EvoPAR-Prostate01 HSPC $5bn+ $5bn+ $5bn+ $5bn+ $5bn+ H1 H1 H1 H1 H2 H2 NME NRA PYR1 Oncology BioPharma 1. Represents non-risk adjusted peak year revenue for the asset, as provided during Investor Day, May 2024. Balcinrenone / dapagliflozin and zibotentan / dapagliflozin are collectively a $5bn+ peak year revenue opportunity. 2. Combined non-risk-adjusted Peak-Year Revenue of all Phase III programmes in 2027, including those depicted on the slide. Indi vidual PYR may occur at different time points for different trials. Collaboration partners: Daiichi Sankyo ( Datroway), Innate Pharma (monalizumab). Appendix: Glossary. 2027 Phase III readouts represent >$20bn in non-risk-adjusted peak year revenue potential2
Page 25
Represents non-risk adjusted peak year revenue, as provided during Investor Day, May 2024 except for tozorakimab and sonesitatug vedotin which were updated at H1 and Q2 2026 results and volrustomig which was updated in September 2026. 1. Peak Year Revenue, non -risk adjusted (Product Sales and Alliance Revenue) across all indications. 2. At Investor Day, total wholly-owned ADC portfolio was presented as a >$5bn NRA PYR opportunity. Includes puxitatug samrotecan and torvutatug samrotecan, wholly-owned ADCs planned to launch by 2030. Collaboration partners: Daiichi Sankyo ( Datroway). Appendix: Glossary. 25 NMEs with pivotal data readouts before 2030 drive growth into and through the next decade Oncology BioPharma Rare Positive Phase III readout Deep late-stage pipeline of multi-blockbuster opportunities >$5bn $3-5bn efzimfotase alfa balcinrenone | zibotentan + dapagliflozin cliramitug tozorakimab saruparib volrustomig laroprovstat franchise rilvegostomig elecoglipron | AZD6234 | AZD9550 1 Wholly-Owned ADCs 2 AZD0120 surovatamig sonesitatug vedotin2
Page 26
Increasing confidence in Ambition 2030 and continued growth beyond 25+ potential blockbuster medicines by 2030 16 delivered in 2025 20 NMEs by 2030 – 14 launched Transformative technologies to drive growth beyond 2030 $80bn 2030 target on track1 13% Total Revenue CAGR since 2023 20+ high value Phase III readouts through 2027 Revenue Delivery Commercial Scale Diverse Pipeline Investing for the Future 26 1. 2030 Total Revenue ambition is risk-adjusted and not dependent upon future M&A. Based on Q1 2024 exchange rates. Appendix: Glossary.
Page 27
Q&A Session Pascal Soriot CHIEF EXECUTIVE OFFICER Aradhana Sarin CHIEF FINANCIAL OFFICER Marc Dunoyer CHIEF EXECUTIVE OFFICER, ALEXION Susan Galbraith EVP , ONCOLOGY HAEMATOLOGY R&D Dave Fredrickson EVP , ONCOLOGY HAEMATOLOGY BUSINESS Sharon Barr EVP , BIOPHARMACEUTICALS R&D Ruud Dobber EVP , BIOPHARMACEUTICALS BUSINESS Iskra Reic EVP , INTERNATIONAL
Page 28
Please ensure you have added the correct confidentiality statement. Type the correct statement: ‘Company Restricted’ or ‘Strictly Confidential’ . No statement is needed for public information. ! Appendix
Page 29
1. Partnered medicines include: Enhertu, Lynparza, Datroway, Beyfortus, Tezspire, Wainua. 2. Core financial measures are adjusted to exclude certain items. The differences between Reported and Core measures are pr imarily due to costs relating to the amortisation of intangibles, impairments, legal settlements and restructuring charges. Appendix: Glossary. 29 AstraZeneca P&L reference table P&L line-item definitions P&L line-item definition Product Sales • Recognises sales from territories where Group has lead commercialisation • Recognises supply of Beyfortus to Sanofi Alliance Revenue • Alliance Revenue comprises income arising from the ongoing operation of collaborative arrangements related to sales made by collaboration partners, where AstraZeneca is entitled to a share of gross profits, share of revenues or royalties, which are recurring in nature while the collaboration agreement remains in place1 Product Revenue • The sum of Product Sales and Alliance Revenue Collaboration Revenue • Recognises any development or sales-based milestone received on partnered medicines as well as any upfront payments associated with business development where AstraZeneca retains a significant ongoing economic interest in the product Total Revenue • Sum of Product Sales, Alliance Revenue and Collaboration Revenue Gross Margin • Calculated by dividing Gross Profit by T otal Revenue Other operating income & expense • Other operating income and expense is generated from activities outside of the Group’s normal course of business, which includes Other income from divestments of or full out-license of assets and businesses including royalties and milestones where the Group does not retain a significant continued interest Core2 Operating margin • Defined as Core Operating profit as a percentage of Total Revenue APPEN DI X | P&L definitions
Page 30
30 Appendix: Glossary. AstraZeneca P&L 2026 P&L modelling considerations P&L line P&L Total Revenue • Expected to grow by a mid-to-high single-digit percentage at CER (guidance) Gross margin • Core gross margin expected to be stable to slightly better vs. 2025 R&D • Core R&D expense expected to be at the upper end of the low 20%s range (of T otal Revenue) Total opex • As in prior years, sequential step-up in operating expenses in Q4 vs. Q3 Other operating income • Slightly higher OOI in H2 2026 vs. H1 2026 Finance expenses • Core Finance expenses anticipated to be higher in Q4, due to Q3 bond issuance, lease expenses and one time cost for premium paid in conjunction with the Summit equity investment Tax • Core tax rate expected to be between 18-22% for the full year Core EPS • Expected to grow by a low double-digit percentage at CER (guidance) FX-impact • If foreign exchange rates for October 2026 to December 2026 were to remain at the average rates seen in September 2026, a low single-digit positive impact is anticipated on T otal Revenue and a neutral impact on Core EPS APPEN DI X | P&L definitions
Page 31
AstraZeneca in non-small cell lung cancer 31 Tagrisso ADAURAEGFRm ~17% IO sensitive ~75% Stg. I Metastatic 1st line 2nd line + Est. epi (G7, 2026) ~152K ~310K ~262K HER2m ~2%2 ~54K ~99K Stg. I-II Stg. III UnresectableResectable Imfinzi AEGEAN SBRT → Imfinzi PACIFIC-4 CRT → Imfinzi + monalizumab/ oleclumab PACIFIC-9 CRT → Tagrisso LAURA CRT → Imfinzi PACIFIC Stg. II-III ~70K Tagrisso ADAURA2 launched and established SoC launched indication DXd ADC IO TKI IO bispecificKey: APPEN DI X | Oncology tumour maps Datroway ± Tagrisso TROPION-Lung15 Tagrisso + Orpathys SAFFRON Zegfrovy WU-KONG1B5 Enhertu DESTINY-Lung02 Datroway TROPION-Lung17 NSQ TROP2-NMR+ Datroway TROPION-Lung05 Enhertu DESTINY-Lung04 Tagrisso +/- CTx FLAURA, FLAURA2 Zegfrovy WU-KONG285 Datroway + Tagrisso TROPION-Lung14 Imfinzi + Imjudo + CTx POSEIDON rilvegostomig ± Datroway TROPION-Lung10 rilvegostomig + CTx PD-L1≥1% AL02 (SQ)/AL03 (NSQ) rilvegostomig PD-L1≥50% ARTEMIDE-Lung04 Datroway + IO ± platinum AVANZAR/TL07/TL08 Enhertu + pembrolizumab PD-L1<50% DESTINY-Lung06 Tagrisso + Orpathys SANOVO3 Ex20ins 10% Ex20ins 10% MET-driven 10-15%4 MET-driven 34%4 TROP2+ 66% HER2+ 22% SBRT → Tagrisso PACIFIC-4 Other tumour drivers ~7%1 1. Among total NSCLC patients. 2. Among mNSCLC patients. 3. China-only trial. 4. MET-driven defined as MET IHC 3+ in 1L and MET IHC 3+ or FISH 10+ in 2L. 5. Trial sponsored by Dizal Pharma. All numbers are approximate. Illustrative settings and populations, not to scale. Lung cancer map reflects Phase III/pivotal trials. Collaboration partners: Daiichi Sankyo ( Enhertu, Datroway), Hutchmed (Orpathys). Appendix: Glossary. Zegfrovy WU-KONG163,5
Page 32
AstraZeneca in EGFRm non-small cell lung cancer 32 Exon 20 insertion mutations ~10% Exon 19 deletions / exon 21 L858R mutations ~75% Other mutations ~15% MetastaticUnresectableResectable Stg. I 1st line 2nd line +Stg. I-II Stg. IIIStg. II-III ~28K ~51K~9K ~15K~11K ~43K launched and established SoC launched indication DXd ADC IO TKI IO bispecificKey: SBRT → Tagrisso PACIFIC-4 Tagrisso ADAURA2 Tagrisso ADAURA CRT → Tagrisso LAURA Zegfrovy WU-KONG283 Tagrisso +/- CTx FLAURA, FLAURA2 Datroway + Tagrisso TROPION-Lung14 Tagrisso + Orpathys SANOVO1 MET-driven 10-15%2 Zegfrovy WU-KONG1B3 Datroway ± Tagrisso TROPION-Lung15 Tagrisso + Orpathys SAFFRON Datroway TROPION-Lung05 MET-driven 34%2 Est. epi (G7, 2026) 1. China-only trial. 2. MET-driven defined as MET IHC 3+ in 1L and MET IHC 3+ or FISH 10+ in 2L. 3. Trial sponsored by Dizal Pharma. All numbers are approximate. Illustrative settings and populations, not to scale. Lung Cancer map reflects Phase III/pivotal trials. Collaboration partners: Daiichi Sankyo ( Enhertu, Datroway), Hutchmed (Orpathys). Appendix: Glossary. Zegfrovy WU-KONG161,3 APPEN DI X | Oncology tumour maps
Page 33
AstraZeneca in breast cancer 33 RECURRENCE gBRCAm 5% of HR-positive 15% of TNBC HER2-positive 15-20% HR-positive 65-75% TNBC 10-15% Est. epi (G7, 2026) 540k 135k 100k 70k 55k 1st line 2nd line 3rd line 4th line + Early Neoadjuvant Adjuvant Metastatic CTx → Lynparza OlympiA Enhertu → THP DESTINY-Breast11 NST → residual disease → Datroway ± Imfinzi TROPION-Breast03 CTx → AI ± CDK4/6i 2-5 yrs → Etcamah CAMBRIA-1 Good outcomes with current SoC for low-risk patients CTx → Etcamah ± abemaciclib CAMBRIA-2 NST residual disease → Enhertu DESTINY-Breast05 PD-L1- 60% PD-L1+ 40%Datroway + Imfinzi TROPION-Breast04 Lynparza OlympiAD Enhertu ± pertuzumab DESTINY-Breast09 Datroway TROPION-Breast02 Datroway + Imfinzi TROPION-Breast05 Enhertu DESTINY-Breast03 Enhertu DESTINY-Breast01/02 Datroway TROPION-Breast01 Enhertu DESTINY-Breast06 HER2-low (1+, 2+) 60% HER2-ultralow (0-1+) 25% Truqap + Faslodex CAPItello291 PIK3CA, AKT1, PTEN alt. 40 % HER2-low (1+, 2+) 35% DESTINY-Breast04 HER2-low (1+, 2+) 35% Enhertu DESTINY-Breast04 HER2-low (1+, 2+) 60% launched and established SoC launched indicationDXd ADC PARPiIO ngSERD AKTiKey: APPEN DI X | Oncology tumour maps PD-L1-inelig. 70% PD-L1-elig. 30% Truqap + Faslodex + CDK4/6i CAPItello292 saruparib + Etcamah EvoPAR-Breast01 tBRCAm, PALB2m 9% AI + CDK4/6i → Etcamah + CDK4/6i SERENA-6 ESR1m 30% All numbers are approximate. Illustrative settings and populations, not to scale. Breast Cancer map reflects Phase III/pivota l trials. Collaboration partners: Daiichi Sankyo ( Enhertu, Datroway), Merck & Co., Inc. (Lynparza). Appendix: Glossary.
Page 34
AstraZeneca in gastric cancer 34 launched and established SoC launched indicationDXd ADC IO AZ ADC IO bispecificKey: APPEN DI X | Oncology tumour maps RECURRENCE Other 30-35% HER2-positive 20% Est. epi (G7, 2026) 50k 90k 60k 30k 1st line 2nd line 3rd line Early Stage II/III/IVa Advanced/Metastatic Imfinzi + perioperative FLOT in resectable disease MATTERHORN Enhertu + rilvegostomig + FP ARTEMIDE-Gastric01 Enhertu + pembrolizumab + FP DESTINY-Gastric05 Enhertu DESTINY-Gastric02, 04 Enhertu DESTINY-Gastric01 sonesitatug vedotin CLARITY-Gastric01 Claudin 18.2- positive 45-50% sonesitatug vedotin + CTx ± rilvegostomig CLARITY-Gastric02 All numbers are approximate. Illustrative settings and populations, not to scale. Gastric cancer map reflects ongoing active Phase III/pivotal trials and includes GC, EAC and GEJC epidemiology. Collaboration partner: Daiichi Sankyo ( Enhertu). Appendix: Glossary.
Page 35
AstraZeneca in bladder cancer 35 launched and established SoC launched indicationDXd ADC IO AZ ADC IO bispecificKey: APPEN DI X | Oncology tumour maps High-risk NMIBC MIBC 1L mUC 149k 81k 63k Imfinzi + BCG induction and maintenance POTOMAC Imfinzi + CTx ± Imjudo NILE Neoadjuvant Imfinzi + EV ± Imjudo → adjuvant Imfinzi ± Imjudo VOLGA Neoadjuvant Imfinzi + CTx → adjuvant Imfinzi NIAGARA Est. epi (G7, 2026) Datroway +/- rilvegostomig TROPION-Urothelial04 ~20% high-risk adjuvant All numbers are approximate. Illustrative settings and populations, not to scale. Appendix: Glossary.
Page 36
36 All numbers are approximate. Illustrative settings and populations, not to scale, based on 2026 GINA recommendation. Patient population and treatment recommendation is defined as per GINA recommendation. However, in some jurisdiction, biologics can be approved to be used at the moderate to severe step ( ie: US, and China). Asthma map reflects Phase III/pivotal trials and selected phase II programmes. Collaboration partners: Amgen ( Tezspire, sunakiment). Appendix: Glossary. launched indication AstraZeneca in asthma APPEN DI X | R&I disease maps Key: Symptom control Maintenance (Inhaled) Novel oral / inhaled / biologics EOS < 150 (25%) EOS 150–300 (30%) EOS > 300 (45%) Mild (Step 1 + 2) Moderate (Step 3) Severe (Step 5) Est. epi (G8, 2026) ~54m treated ~3.6m ICS-LABA (maintenance) ICS monotherapy Anti-inflammatory reliever Triple (ICS-LABA-LAMA) Anti-IL-5 (biologic) TSLP (biologic) Rescue / Reliever (Inhaled) ~25m Airsupra Symbicort Symbicort Breztri/Trixeo IL-33 (biologic) TSLP (inhaled biologic) Symbicort Moderate to severe (Step 4) Airsupra Symbicort Tezspire tozorakimab; UMBRIEL Phase II sunakiment; LEVANTE Phase II Symbicort Airsupra Symbicort Pulmicort Airsupra Symbicort Fasenra
Page 37
37 All numbers are approximate. Illustrative settings and populations, not to scale. COPD map reflects Phase II or Phase III /pi votal trials. Approved product categorisation based on GOLD 2026 treatment guidelines 1. Breztri currently recommended to be used in patients on ICS/LABA therapy with no exacerbations in prior 12m who are still symptomatic . Collaboration partners: Amgen (Tezspire / tezepelumab). Appendix: Glossary. launched indication AstraZeneca in COPD APPEN DI X | R&I disease maps Key: Dual inhaler Triple inhaler TSLP (biologic) IL-33 (biologic) Exacerbation History (prior 12 mos) Maintenance (Inhaled) Novel oral / inhaled / biologics EOS < 150 (35%) EOS 150–300 (35%) EOS > 300 (30%) 0 exacerbations 1 moderate exacerbation ≥2 moderate or ≥1 severe exacerbation AZD6793; PRESTO Phase II tezepelumab; EMBARK / JOURNEY Phase III Est. epi (G8, 2026) ~40m treated ~4.6m Bevespi Bevespi Breztri tozorakimab; OBERON / TITANIA / MIRANDA Phase III IRAK4i (oral) Breztri Breztri1 Breztri; THARROS Phase III TQC3721 PDE3/4 (inhaled) Add on therapy
Page 38
38 Due to rounding, the sum of a number of dollar values and percentages may not agree to totals. Collaboration partner: Merck & Co., Inc. ( Lynparza). Appendix: Glossary. Oncology Tagrisso 8% growth at CER to $5,862m in 9M 2026 Lynparza 2% decrease at CER to $2,421m in 9M 2026 APPEN DI X | Product Revenue Performance Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2024 2025 2026 EM 446 391 519 489 501 462 536 512 608 ERoW 186 201 175 209 207 206 177 202 191 Europe 328 344 307 351 372 393 387 382 400 US 714 767 678 761 784 841 733 846 888 0 500 1,000 1,500 2,000 2,500 Product Revenue ($m) Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2024 2025 2026 EM 155 180 161 162 164 182 174 169 164 ERoW 62 66 57 69 66 69 60 68 64 Europe 214 220 196 229 242 247 239 241 230 US 347 378 312 378 365 380 308 351 353 0 100 200 300 400 500 600 700 800 900 1,000 Product Revenue ($m)
Page 39
39 Oncology APPEN DI X | Product Revenue Performance Imfinzi 27% growth at CER to $5,538m in 9M 2026 Imjudo 4% growth at CER to $263m in 9M 2026 Due to rounding, the sum of a number of dollar values and percentages may not agree to totals. Appendix: Glossary. Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2024 2025 2026 EM 120 113 142 152 169 178 187 211 229 ERoW 167 167 139 174 178 185 170 191 212 Europe 236 253 252 285 342 359 383 398 429 US 680 721 728 844 912 1,025 954 1,054 1,120 0 500 1,000 1,500 2,000 2,500 Product Revenue ($m) Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2024 2025 2026 EM 4 5 5 7 6 5 6 7 20 ERoW 12 13 11 13 10 10 9 10 11 Europe 10 10 11 12 13 16 13 15 15 US 46 45 53 57 55 62 49 51 57 0 20 40 60 80 100 120 Product Revenue ($m)
Page 40
40 Due to rounding, the sum of a number of dollar values and percentages may not agree to totals. Collaboration partner: D aiichi Sankyo (Enhertu). Appendix: Glossary. Oncology APPEN DI X | Product Revenue Performance Calquence 16% growth at CER to $3,009m in 9M 2026 Enhertu 33% growth at CER to $2,688m in 9M 2026 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2024 2025 2026 EM 41 37 54 49 61 69 70 67 77 ERoW 33 31 31 42 43 46 36 43 44 Europe 169 167 170 198 200 215 218 224 248 US 570 573 507 583 612 637 599 687 696 0 200 400 600 800 1,000 1,200 Product Revenue ($m) Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2024 2025 2026 EM 128 125 172 192 225 240 261 268 320 ERoW 16 22 19 23 21 41 46 49 26 Europe 136 142 146 166 177 176 207 194 195 US 229 250 258 284 291 342 317 377 428 0 200 400 600 800 1,000 1,200 Product Revenue ($m)
Page 41
41 BioPharmaceuticals: Respiratory & Immunology APPEN DI X | Product Revenue Performance Fasenra 13% growth at CER to $1,655m in 9M 2026 Tezspire 44% growth at CER to $1,123m in 9M 2026 Saphnelo 27% growth at CER to $615m in 9M 2026 Due to rounding, the sum of a number of dollar values and percentages may not agree to totals. Collaboration partner: Amgen ( Tezspire). Appendix: Glossary. Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2024 2025 2026 EM 3 2 3 4 4 6 5 6 7 ERoW 4 5 4 6 7 7 7 8 9 Europe 7 9 9 12 13 15 17 19 21 US 110 131 120 145 156 175 142 176 198 0 50 100 150 200 250 Product Revenue ($m) Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2024 2025 2026 EM 27 23 27 26 28 36 46 46 57 ERoW 36 39 39 44 50 54 52 57 59 Europe 102 110 103 125 122 131 129 129 131 US 271 299 249 307 330 309 256 338 355 0 100 200 300 400 500 600 700 Product Revenue ($m) Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2024 2025 2026 EM 3 4 7 9 8 16 20 24 20 ERoW 22 25 23 31 32 35 34 41 48 Europe 43 51 57 72 79 90 95 107 120 US 123 133 130 155 168 220 154 219 241 0 50 100 150 200 250 300 350 400 450 500 Product Revenue ($m)
Page 42
42 BioPharmaceuticals: Respiratory & Immunology APPEN DI X | Product Revenue Performance Breztri 16% growth at CER to $1,073m in 9M 2026 Symbicort 7% decrease at CER to $2,084m in 9M 2026 Due to rounding, the sum of a number of dollar values and percentages may not agree to totals. Appendix: Glossary. Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2024 2025 2026 EM 68 45 90 65 83 59 115 93 121 ERoW 19 21 20 25 24 27 25 30 27 Europe 37 42 42 46 49 55 64 63 56 US 142 149 148 147 167 153 149 160 170 0 50 100 150 200 250 300 350 400 Product Revenue ($m) Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2024 2025 2026 EM 203 153 232 168 224 177 226 191 236 ERoW 83 88 77 91 78 84 79 81 74 Europe 130 144 135 137 135 154 152 144 129 US 289 299 279 319 305 289 290 255 227 0 100 200 300 400 500 600 700 800 Product Revenue ($m)
Page 43
43 BioPharmaceuticals: Cardiovascular, Renal & Metabolism APPEN DI X | Product Revenue Performance Farxiga 15% decrease at CER to $5,603m in 9M 2026 Brilinta 62% decrease at CER to $261m in 9M 2026 Lokelma 23% growth at CER to $638m in 9M 2026 Due to rounding, the sum of a number of dollar values and percentages may not agree to totals. Appendix: Glossary. Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2024 2025 2026 EM 750 628 871 859 893 701 923 695 582 ERoW 108 103 121 107 103 79 43 83 97 Europe 670 731 683 765 698 794 778 808 799 US 411 472 383 420 441 486 449 219 127 0 500 1,000 1,500 2,000 2,500 Product Revenue ($m) Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2024 2025 2026 EM 66 62 74 63 66 71 76 66 65 ERoW 5 6 3 2 2 2 2 2 1 Europe 67 65 55 51 23 18 13 11 9 US 189 208 173 99 55 67 14 2 0 0 50 100 150 200 250 300 350 400 Product Revenue ($m) Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2024 2025 2026 EM 26 18 30 33 36 30 45 48 56 ERoW 26 31 28 37 36 38 34 41 39 Europe 25 26 26 30 35 38 41 46 49 US 66 75 69 75 82 75 79 85 75 0 50 100 150 200 250 Product Revenue ($m)
Page 44
44 Due to rounding, the sum of a number of dollar values and percentages may not agree to totals. Collaboration partner: Merck & Co., Inc. ( Koselugo) concluded in August 2025. Appendix: Glossary. Rare Disease APPEN DI X | Product Revenue Performance Ultomiris 16% growth at CER to $4,016m in 9M 2026 Strensiq 37% growth at CER to $1,641m in 9M 2026 Koselugo 15% growth at CER to $585m in 9M 2026 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2024 2025 2026 EM 26 49 52 61 64 84 103 87 116 ERoW 170 173 166 179 200 192 190 201 214 Europe 238 235 228 270 271 284 298 307 310 US 597 632 604 667 690 705 679 719 792 0 200 400 600 800 1,000 1,200 1,400 1,600 Product Revenue ($m) Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2024 2025 2026 EM 25 69 40 36 113 39 61 54 110 ERoW 10 11 11 12 16 16 18 21 23 Europe 29 29 34 37 44 46 49 50 50 US 55 56 53 52 51 62 42 52 55 0 50 100 150 200 250 Product Revenue ($m) Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2024 2025 2026 EM 8 15 34 16 11 43 49 16 46 ERoW 24 27 26 29 29 34 29 32 33 Europe 25 26 26 31 32 34 32 36 36 US 286 352 266 319 369 379 407 452 473 0 100 200 300 400 500 600 700 Product Revenue ($m)
Page 45
Glossary 1L, 2L, 3L first-, second -, third -line 9M first nine months ACM all-cause mortality ADC antibody -drug conjugate AI aromatase inhibitor AKT1 AKT serine/threonine kinase 1 AKTi AKT inhibitor AL-A light chain amyloidosis alt. alteration ATTR-CM transthyretin amyloid cardiomyopathy ATTR-PN transthyretin amyloid polyneuropathy AZ AstraZeneca BCG Bacillus Calmette -Guérin BEC blood eosinophil count BTKi Bruton's tyrosine kinase inhibitor C5 complement component 5 CAGR compound annual growth rate CapEx capital expenditure CDK4/6i cyclin-dependent kinase 4/6 inhibitor CER constant exchange rates CFO net cash inflow from operating activities CHMP Committee for Medicinal Products for Human Use CKD chronic kidney disease CLDN18.2 Claudin -18.2 CLL chronic lymphocytic leukaemia CN China COPD chronic obstructive pulmonary disease CR Collaboration Revenue CRT chemoradiotherapy CTx chemotherapy CV cardiovascular CVRM Cardiovascular, Renal and Metabolism DLBCL diffuse large B -cell lymphoma DSQ Dysphagia Symptom Questionna ire DXd deruxteca n eBC early breast cancer EBITDA Reported Profit before tax after adding back net finance expense, results from joint ventures and associates, and charges for depreciation, amortisation and impairment EGFRm epidermal growth factor receptor -mutant EGPA eosinophilic granulomatosis with polyangiitis EM Emerging Markets EoE eosinophilic esophagitis EOS eosinophils epi epidemiology EPS earnings per share NMIBC non-muscle invasive bladder ca ncer NMR+ normalised membrane ratio positive NRA non-risk-adjusted NSCLC non-small cell lung cancer NSQ non-squamous NST neoadjuvant systemic therapy OOI other operating income OS overall survival P&L profit and loss PALB2m partner and localiser of BRCA2 -mutated PARPi poly-ADP ribose polymerase inhibitor PD-L1 / PDL1 programmed cell death ligand 1 PDE3/4 phosphodiesterase 3 and 4 inhibitor PIK3CA phosphatidylinositol 3 -kinase catalytic subunit alpha pp percentage point PR Product Revenue PS Product Sales PTEN phosphatase and TENsin homolog deleted on chromosome 10 PYR Peak-Year Revenue Q4W every four weeks R&D Research & Development R&I Respiratory & Immunology s.c. subcutaneous SBRT stereotactic body radiotherapy SCLC / ES -SCLC small cell lung cancer / extensive -stage small cell lung cancer SG&A Selling, General & A dministrative SoC standard -of-care SQ squamous Stg. stage tBRCAm tumour BRCA mutation TCE T-cell engager THP docetaxel, trastuzumab and pertuzumab TKI tyrosine kinase inhibitor TL07 TROPION -Lung07 TL08 TROPION -Lung08 TNBC triple negative breast cancer TROP2 trophoblast cell surface antigen 2 TSLP thymic stromal lymphopoietin TTR transthyretin UEGW United European Gastroenterology Week US United States VBP volume -based procurement WCLC World Conference on Lung Cancer YTD year to date ERoW Esta blished Rest of World ESMO European Society for Medical Oncology ESR1m estrogen receptor alpha -mutated Est. estimated EU Europe FDC fixed-dose combination FLOT fluorouracil, leucovorin, oxaliplatin and docetaxel FP fluoropyrimidine FX foreign exchange FY Full Year G7 US, Japan and EU5 G8 US, Japan, EU5 and China gBRCAm germline BRCA -mutated GINA Global Initiative for Asthma gMG genera lised myasthenia gravis GOLD Global Initiative for Chronic Obstructive Lung Disease H1, H2 first half, second half HCC hepatocellular carcinoma HER2 human epidermal growth factor receptor 2 HER2+/positive human epidermal growth factor receptor 2 -positive HER2-low human epidermal growth factor receptor 2 -low HER2-ultralow human epidermal growth factor receptor 2 -ultralow HER2m human epidermal growth factor receptor 2 -mutant HF heart failure HPP hypophosphatasia HR+/positive hormone receptor -positive HSPC hormone -sensitive prostate cancer i.v. intravenous ICS inhaled corticosteroid ID Infectious Disease IgAN immunoglobulin A nephropathy IL-33 interleukin -33 IL-5 interleukin -5 IO immuno -oncology IRAK4i interleukin -1 receptor -associated kinase 4 inhibitor JP Japan LABA long-acting beta2 -agonist LAMA long-acting muscarinic antagonist LoE loss of exclusivity MIBC muscle invasive bladder ca ncer MoA mechanism of action mUC metastatic urothelial carcinoma ngSERD next-genera tion selective estrogen receptor degrader NME new molecular entity APPEN DI X | Glossary
Page 46
Confidentiality Notice This file is private and may contain confidential and proprietary information. If you have received this file in error , please notify us and remove it from your system and note that you must not copy, distribute or take any action in reliance on it. Any unauthorized use or disclosure of the contents of this file is not permitted and may be unlawful. AstraZeneca PLC, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA, UK +44(0)203 749 5000 www.astrazeneca.com 46